APOE ε4 does not predict mortality, cognitive decline, or dementia in the oldest old
Abstract
Objective To examine the effect of the epsilon 4 allele on cognitive decline in the oldest old. Methods We studied all 601 citizens of the city of Vantaa age 85 years and older in 1991. A total of 553 subjects (92%) took part in the study, which used the Mini-Mental State Examination (MMSE) and assessment of dementia according to the Diagnostic and Statistical Manual of Mental Disorders, third ed., revised (DSM-III-R) criteria. The survivors were re-examined 3 years later. APOE genotype was determined in 510 subjects, representing 83.2% of the original population. Results Approximately one-half of the subjects (n = 250) died before the follow-up, and 253 subjects (97.3% of the survivors) were re-examined. The occurrence of the APOE epsilon 4 allele did not have any significant effect on survival. Of the 187 previously nondemented subjects, 58 (31%) had developed dementia. The OR for the epsilon 4 carriers to develop dementia was not significant: OR = 1.78; 95% CI = 0.88 to 3.60. In individuals with a follow-up MMSE score (n = 222), the mean decline in the score was 3.1 points. APOE epsilon 4 carrier status did not have a significant effect on the mean MMSE change except in the previously demented subjects, among whom the drop was larger in the APOE epsilon 4 carriers. Conclusions The lack of association between APOE epsilon 4 carrier status and mortality, or development of dementia, or cognitive decline in these very elderly people, whether analyzed in the whole population or…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some studies suggest that the effect of the ε4 allele on cognitive decline is stronger in the earlier clinical stages of disease and is weaker during the later and more severe clinical stages.
“Some studies suggest that the effect of the ε4 allele on cognitive decline is stronger in the earlier clinical stages of disease and is weaker during the later and more severe clinical stages (Cosentino et al., 2008; Juva et al., 2000).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Juva et al., 2000
Cites
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · see citing works
Dementia incidence continues to increase with age in the oldest old: The 90+ study
Corrada, M. M., Brookmeyer, R., Paganini‐Hill, A., Berlau, D., & Kawas, C. H. (2010) · Annals of Neurology · doi:10.1002/ana.21915 · Cited by 523 · see citing works
Independent predictors of cognitive decline in healthy elderly persons
Marquis, S., Moore, M. M., Howieson, D. B., Sexton, G., Payami, H., Kaye, J. A., & Camicioli, R. (2002) · Archives of Neurology · doi:10.1001/archneur.59.4.601 · Cited by 344 · see citing works
Higher Rates of Decline for Women and <i>Apolipoprotein E</i> ε4 Carriers
Holland, D., Desikan, R. S., Dale, A. M., & McEvoy, L. K. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3601 · Cited by 219 · see citing works
Microstructural white matter changes in cognitively normal individuals at risk of amnestic MCI
Zhuang, L., Sachdev, P. S., Trollor, J. N., Kochan, N. A., Reppermund, S., Brodaty, H., & Wen, W. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661f4d · Cited by 125 · see citing works
Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study
Kramer, P. L., Xu, H., Woltjer, R. L., Westaway, S. K., Clark, D., Erten-Lyons, D., Kaye, J. A., Welsh-Bohmer, K. A., Troncoso, J. C., Markesbery, W. R., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.01.010 · Cited by 108 · see citing works
Morphological substrates of cognitive decline in nonagenarians and centenarians: A new paradigm?
Imhof, A., Kövari, E., von Gunten, A., Gold, G., Rivara, C.-B., Herrmann, F. R., Hof, P. R., Bouras, C., & Giannakopoulos, P. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.025 · Cited by 106 · see citing works
von Gunten, A., Ebbing, K., Imhof, A., Giannakopoulos, P., & Kövari, E. (2010) · Current Gerontology and Geriatrics Research · doi:10.1155/2010/358531 · Cited by 62 · see citing works
Rajan, K. B., Barnes, L. L., Wilson, R. S., McAninch, E. A., Weuve, J., Sighoko, D., & Evans, D. A. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15059 · Cited by 59 · see citing works
- Authors
- Juva, K., Verkkoniemi, A., Viramo, P., Polvikoski, T., Kainulainen, K., Kontula, K., & Sulkava, R.
- Affiliations
- University of Helsinki (FI)
- ORCID
- Kontula, K.
- Venue
- Neurology
- Published
- 2000-01-25
- Volume
- 54
- Issue
- 2
- Pages
- 412-412
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1980929918
- Cited by
- 108
- References
- 1
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 2 · 2023: 1 · 2021: 3 · 2020: 5 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 4 · 2015: 4 · 2014: 2 · 2013: 3 · 2012: 3
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Aging and Gerontology Research
- Keywords
- APOE ε4, oldest old, dementia, cognitive decline, mortality, APOE genotype, Mini-Mental State Examination
- MeSH terms
- Aged, Aged, 80 and over, Alleles, Apolipoproteins E, Cognition Disorders, Dementia, Female, Follow-Up Studies, Humans, Male, Predictive Value of Tests, Prospective Studies, Psychiatric Status Rating Scales, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review